Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29) Fusion

Intergenic-gene fusion detected by DNA-seq is particularly confusing for drug selection since the function of the intergenic region located upstream is unknown. We reported a case of a 49-year-old male with advanced lung adenocarcinoma, who was detected FBXO11 (intergenic)-ALK (exon 20-29) by DNA-se...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jing, Yao, Youyuan, Quan, Fei, Lu, Zhongyu, Wang, Jian, Gao, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335319/
https://www.ncbi.nlm.nih.gov/pubmed/37441362
http://dx.doi.org/10.2147/OTT.S406234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335319/
https://www.ncbi.nlm.nih.gov/pubmed/37441362
http://dx.doi.org/10.2147/OTT.S406234

Ejemplares similares